Search Within

Sarat Chandarlapaty

  1. "Pamela Drullinsky"
Formats
  1. Meeting Abstract (6)
  2. Journal Article (2)
Groups
  1. Alan and Sandra Gerry Metastasis and Tumor Ecosystems Center (8)
  2. Breast Medicine Service (8)
  3. Department of Medicine (8)
  4. GSK Faculty (8)
  5. Human Oncology and Pathogenesis Program (8)
  6. Solid Tumor Oncology Division (8)

More Groups

People
  1. Pamela Drullinsky (8)
  2. Clifford Hudis (7)
  3. Sujata Patil (7)
  4. Shanu Modi (6)
  5. Angemael Syldor (4)
  6. Chau Dang (4)

More People

Years
  1. 2016 (1)
  2. 2015 (1)
  3. 2014 (1)
  4. 2012 (3)
  5. 2011 (2)
Publications
  1. Cancer Research (4)
  2. Journal of Clinical Oncology (2)
  3. Breast Cancer Research and Treatment (1)
  4. Clinical Breast Cancer (1)
Publishers
  1. American Association for Cancer Research (4)
  2. American Society of Clinical Oncology (2)
  3. Elsevier Inc. (1)
  4. Springer (1)

Results (8)


Citation style sort is year ascending, and then by author or title. Author ascending is default.
  • Weekly paclitaxel with trastuzumab and pertuzumab in patients with HER2-overexpressing metastatic breast cancer: Overall survival and updated progression-free survival results from a phase II study
    Journal Article

    Smyth, L. M.; Iyengar, N. M.; Chen, M. F.; Popper, S. M.; Patil, S.; Wasserheit-Lieblich, C.; Argolo, D. F.; Singh, J. C.; Chandarlapaty, S.; Sugarman, S. M.; more...
    Breast Cancer Research and Treatment (2016)

    Fulltext@MSK | Save
  • Phase II study of weekly paclitaxel with trastuzumab and pertuzumab in patients with HER2-overexpressing metastatic breast cancer (MBC): Updated progression-free survival with overall survival result
    Meeting Abstract

    Smyth, L. M.; Iyengar, N. M.; Chandarlapaty, S.; Sugarman, S.; Comen, E. A.; Drullinsky, P.; Sklarin, N. T.; Traina, T. A.; Troso-Sandoval, T. A.; Patil, S.; more...
    Journal of Clinical Oncology (2015)

    Fulltext@MSK | Save
  • A phase II open-label study of ganetespib, a novel heat shock protein 90 inhibitor for patients with Metastatic breast cancer
    Journal Article

    Jhaveri, K.; Chandarlapaty, S.; Lake, D.; Gilewski, T.; Robson, M.; Goldfarb, S.; Drullinsky, P.; Sugarman, S.; Wasserheit Leiblich, C.; Fasano, J.; more...
    Clinical Breast Cancer (2014)

    Fulltext@MSK | Save
  • Phase II study of pertuzumab, trastuzumab, and weekly paclitaxel in patients with HER2-overexpressing metastatic breast cancer (MBC)
    Meeting Abstract

    Datko, F. M.; D'Andrea, G.; Dickler, M. N.; Theodoulou, M.; Goldfarb, S. B.; Lake, D.; Fornier, M. N.; Modi, S.; Sklarin, N. T.; Comen, E. A.; more...
    Journal of Clinical Oncology (2012)

    Fulltext@MSK | Save
  • Tolerability and efficacy of targeting both mTOR and HER2 signaling in trastuzumab-refractory HER2+ metastatic breast cancer
    Meeting Abstract

    Gajria, D.; King, T.; Pannu, H.; Sakr, R.; Modi, S.; Drullinsky, P.; Syldor, A.; Patil, S.; Seidman, A.; Norton, L.; more...
    Cancer Research (2012)

    Fulltext@MSK | Save
  • Phase II study of pertuzumab, trastuzumab, and weekly paclitaxel in patients with metastatic HER2-overexpressing metastatic breast cancer
    Meeting Abstract

    Datko, F.; D'Andrea, G.; Dickler, M.; Theodoulou, M.; Goldfarb, S.; Lake, D.; Fornier, M.; Modi, S.; Sklarin, N.; Comen, E.; more...
    Cancer Research (2012)

    Fulltext@MSK | Save
  • Combined inhibition of mTORC1 with temsirolimus and HER2 with neratinib: A phase I/II study in patients with metastatic HER2-amplified or triple-negative breast cancer
    Meeting Abstract

    Gajria, D.; King, T.; Pannu, H.; Sakr, R.; Seidman, A. D.; Modi, S.; Dickler, M.; Drullinsky, P.; Syldor, A.; Sujata, P.; more...
    Cancer Research (2011)

    Fulltext@MSK | Save
  • A phase II trial of ganetespib: Efficacy and safety in patients (pts) with metastatic breast cancer (MBC)
    Meeting Abstract

    Jhaveri, K.; Chandarlapaty, S.; Lake, D.; Gilewski, T.; Drullinsky, P.; Sugarman, S.; Wasserheit-Leiblich, C.; Moynahan, M. E.; D'Andrea, G.; Haque, S.; more...
    Cancer Research (2011)

    Fulltext@MSK | Save